Alexander Shulgin Research Institute has described phenylalkylamine compounds reported to be useful for the treatment of pain, inflammation, neurodegeneration, stroke, ischemia-reperfusion injury and psychiatric disorders.

University of Washington has divulged compounds acting as methionyl-tRNA synthetase (bacterial) inhibitors reported to be useful for the treatment of bacterial and protozoal infections.

Beijing Double-Crane Runchuang Technology Co. Ltd. has identified fascin (FSCN1) inhibitors reported to be useful for the treatment of cancer.

Odyssey Therapeutics Inc. has synthesized CDK2/cyclin E1 inhibitors reported to be useful for the treatment of cancer.

Researchers at Chengdu Brilliant Pharmaceutical Co. Ltd. and Scinnohub Pharmaceutical Co. Ltd. have disclosed 15-hydroxyprostaglandin dehydrogenase inhibitors reported to be useful for the treatment of diabetes, osteoporosis and more.

Genescience Pharmaceuticals Co. Ltd. has identified fibroblast growth factor receptor 2 (FGFR2) and/or FGFR3 inhibitors reported to be useful for the treatment of cancer, osteochondrodysplasia and achondroplasia.

Quantx Biosciences US Inc. has described poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.

Scientists at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have divulged compounds acting as Toll-like receptor 7 (TLR7) and TLR8 agonists reported to be useful for the treatment of cancer.

Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has synthesized sodium-bile acid cotransporter (SLC10A1; NTCP) inhibitors reported to be useful for the treatment of cardiovascular, fatty acid oxidation, liver and gastrointestinal disorders.

Insilico Medicine Inc. has disclosed NLRP3 inflammasome inhibitors reported to be useful for the treatment of autoimmune and inflammatory disorders.